Name | Number of supported studies | Average coverage | |
---|---|---|---|
type I pneumocyte | 12 studies | 62% ± 25% | |
type II pneumocyte | 10 studies | 53% ± 18% |
Insufficient scRNA-seq data for expression of CLDN18 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 93% | 87.63 | 304 / 328 | 78% | 328.17 | 139 / 178 |
lung | 100% | 15742.15 | 578 / 578 | 62% | 95.10 | 720 / 1155 |
stomach | 100% | 46124.33 | 358 / 359 | 57% | 373.98 | 164 / 286 |
esophagus | 88% | 86.68 | 1274 / 1445 | 61% | 327.52 | 112 / 183 |
intestine | 85% | 90.12 | 821 / 966 | 33% | 155.88 | 174 / 527 |
bladder | 100% | 64.33 | 21 / 21 | 12% | 10.05 | 62 / 504 |
uterus | 100% | 94.34 | 170 / 170 | 3% | 2.69 | 13 / 459 |
ureter | 0% | 0 | 0 / 0 | 100% | 30.44 | 1 / 1 |
ovary | 99% | 108.64 | 179 / 180 | 0% | 0.21 | 1 / 430 |
blood vessel | 95% | 68.24 | 1272 / 1335 | 0% | 0 | 0 / 0 |
prostate | 93% | 53.40 | 227 / 245 | 1% | 0.05 | 4 / 502 |
kidney | 91% | 48.06 | 81 / 89 | 2% | 0.09 | 18 / 901 |
thymus | 92% | 43.74 | 599 / 653 | 0% | 0.06 | 3 / 605 |
skin | 90% | 47.10 | 1632 / 1809 | 2% | 0.13 | 9 / 472 |
breast | 88% | 52.69 | 406 / 459 | 1% | 0.16 | 14 / 1118 |
adipose | 84% | 48.89 | 1013 / 1204 | 0% | 0 | 0 / 0 |
spleen | 78% | 27.26 | 187 / 241 | 0% | 0 | 0 / 0 |
heart | 71% | 123.29 | 611 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 61% | 16.79 | 158 / 258 | 0% | 0 | 0 / 230 |
liver | 34% | 8.87 | 76 / 226 | 6% | 2.89 | 23 / 406 |
brain | 38% | 14.68 | 1007 / 2642 | 0% | 0.02 | 3 / 705 |
peripheral blood | 17% | 6.61 | 156 / 929 | 0% | 0 | 0 / 0 |
muscle | 16% | 4.89 | 128 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 7% | 0.34 | 3 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050673 | Biological process | epithelial cell proliferation |
GO_0035265 | Biological process | organ growth |
GO_0045779 | Biological process | negative regulation of bone resorption |
GO_2001205 | Biological process | negative regulation of osteoclast development |
GO_0071391 | Biological process | cellular response to estrogen stimulus |
GO_0007155 | Biological process | cell adhesion |
GO_0045471 | Biological process | response to ethanol |
GO_0042045 | Biological process | epithelial fluid transport |
GO_0016338 | Biological process | calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules |
GO_0120193 | Biological process | tight junction organization |
GO_0034504 | Biological process | protein localization to nucleus |
GO_0070830 | Biological process | bicellular tight junction assembly |
GO_0048565 | Biological process | digestive tract development |
GO_1900181 | Biological process | negative regulation of protein localization to nucleus |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_0048286 | Biological process | lung alveolus development |
GO_0005886 | Cellular component | plasma membrane |
GO_0005911 | Cellular component | cell-cell junction |
GO_0016328 | Cellular component | lateral plasma membrane |
GO_0005923 | Cellular component | bicellular tight junction |
GO_0042802 | Molecular function | identical protein binding |
GO_0005198 | Molecular function | structural molecule activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CLDN18 |
Protein name | Claudin-18 Claudin |
Synonyms | UNQ778/PRO1572 |
Description | FUNCTION: Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription (By similarity). Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency (By similarity). Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways (By similarity). .; FUNCTION: [Isoform A1]: Involved in the maintenance of homeostasis of the alveolar microenvironment via regulation of pH and subsequent T-cell activation in the alveolar space, is therefore indirectly involved in limiting C. neoformans infection. .; FUNCTION: [Isoform A2]: Required for the formation of the gastric paracellular barrier via its role in tight junction formation, thereby involved in the response to gastric acidification. . FUNCTION: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. . |
Accessions | ENST00000343735.8 [P56856-2] ENST00000183605.10 [P56856-1] F8WEY4 ENST00000479660.1 P56856 |